PubMed · 2006 · 116 citations · 66 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic Nuclear MedicineDiagnostic RadiologyCell Proliferation ImagingLymphoma ImagingMolecular Imaging In OncologyOncologic Nuclear ImagingPositron Emission TomographyTumor ImagingCellular ProliferationHodgkin Lymphoma ImagingLymphoma StagingNon-hodgkin Lymphoma ImagingOncologic Pet ImagingPositron-emitting Radionuclides
Malignant lymphomas are a heterogeneous group of diseases whose treatment and prognosis depend on accurate staging and evaluation of histologic features. The conventional imaging procedure is CT; however, nuclear medicine imaging has also had a prominent role. Single-photon imaging with 67Ga-citrate has been widely used for lymphomas. PET with 18F-FDG has gained a role in the staging and follow-up of lymphomas, largely replacing gallium as the nuclear medicine study of choice. 18F-FDG PET has proved useful in the staging and follow-up of Hodgkin's disease and non-Hodgkin's lymphoma (especially more aggressive types), and the widespread use of PET/CT has also increased the sensitivity and specificity. Its usefulness for the staging of slow-growing lymphomas has not been established. After the basics of staging and classification of lymphomas have been outlined, this article will review the role of 18F-FDG PET in the management of patients with lymphoma. PET tracers other than (18)F-FDG, such as positron-emitting isotopes of gallium and the cellular proliferation marker 18F-3'-deoxy-3'-fluorothymidine, will be discussed and future directions for PET in lymphoma proposed.
66
Otto Warbürg · Science · 1956 · 13.3K citations
Ahmedin Jemal, Thomas S. Murray, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2005 · 5.5K citations · Full text
Report of the Committee on Hodgkin's Disease Staging Classification.
Paul P. Carbone, Henry S. Kaplan, K. Musshoff et al. · PubMed · 1971 · 4.2K citations